Unicycive Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Current Report on Form 8-K regarding Nasdaq continued-listing compliance. The event occurred on July 25, 2023; the report was signed on July 26, 2023. The company is listed on the Nasdaq Capital Market under the symbol UNCY.
Key Financial and Operating Metrics
This filing does not report revenue, profitability, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Change Versus the Prior Period
On May 17, 2023, Nasdaq notified the company that it was not compliant with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35 million over 30 consecutive business days.
Nasdaq determined that the company’s market value of listed securities was at least $35 million for 10 consecutive business days from July 11 through July 24, 2023. On July 25, 2023, Nasdaq notified the company that it had regained compliance with the minimum market value requirement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. Regaining compliance addresses the identified Nasdaq listing deficiency, but future compliance may depend on maintaining the applicable market value requirement. The filing does not describe any additional contingencies or unusual financial items.
Investor Verification Checklist
- Verify the company’s continued compliance with Nasdaq Listing Rule 5550(b)(2) after July 25, 2023.
- Review subsequent filings for any additional Nasdaq deficiency notices or listing-status developments.
- Consult the company’s periodic financial filings for cash position, liquidity, operating losses, financing needs, and other financial metrics not provided in this 8-K.